Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is among the 7 Oversold Pharma Stocks to Buy Now.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) tops our list for being one of the oversold stocks.

TheFly reported on February 18 that Evercore ISI reinstated coverage of BCRX with an Outperform rating and a $17 price target. The analyst pointed out that BCRX is well-positioned for long-term growth with the recent acquisition of Astria Therapeutics, pointing out that Orladeyo may reach peak sales of $900 million by 2029 and that Navenibart may generate $1 billion in risk-adjusted revenue.

Separately, earlier on February 11, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that it will feature nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, scheduled for February 27 to March 2.

Six abstracts on ORLADEYO (berotralstat) are included in the presentations; these abstracts address real-world and clinical trial outcomes, including pediatric data for kids two years of age and older. One late-breaking presentation on March 1 reported interim results from the long-term ALPHA-SOLAR trial, showing sustained HAE attack suppression with dosing every three or six months. Three other abstracts center on navenibart, a long-acting monoclonal antibody that targets plasma kallikrein.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biopharmaceutical company focused on developing oral and small-molecule therapies for rare diseases and serious conditions, including antiviral and complement system disorders.

While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

.

and 

.

Disclosure: None.